France to Ban HHC Synthetic Cannabis in Weeks

May.16.2023
France to Ban HHC Synthetic Cannabis in Weeks
France's Health Minister plans to ban HHC products, created from synthetic cannabis extract, within weeks due to regulatory loopholes.

Statement:


This article is solely focused on conducting research on related industries and foreign markets. It does not make recommendations on any products, nor does it provide commentary on any domestic policies pertaining to the industry.


The legality of the product mentioned in the article is limited to overseas only. Domestic readers are reminded to strictly abide by relevant laws and regulations in China.


This article does not provide any investment or consumption advice.


This article is not suitable for minors.


On May 15th, François Braun, the French Minister of Health, announced that products containing HHC (hexahydrocannabinol) may be banned in a few weeks.


When asked about issues related to hexahydrocannabinol (HHC) by the media, Braun told French radio station, "...


I believe that this (ban) will only be in effect for a few weeks.


According to reports, HHC is a molecule artificially synthesized from natural cannabis extract, and products based on HHC are currently not subject to sales or consumption restrictions in France.


In the past few months, health authorities in various countries, both in Europe and the United States, have noticed an increase in the sale of a certain substance through online or physical stores. Currently, not much is known about its effects, but addiction experts believe it has similar effects to tetrahydrocannabinol (THC), which is the primary psychoactive ingredient in cannabis.


Braun explained, "Currently, they are not classified as drugs. But I believe they will soon be.


Braun likened HHC to a regulatory loophole.


There is a loophole that needs to be quickly filled so that we no longer have such completely abnormal sales.


Reference:


The Health Minister announces that synthetic cannabis, HHC, will be banned within a few weeks.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Isle of Wight councillors raise concerns about youth vaping; one says it may be seen “akin to asbestos”
Concerns about the effects of vaping on young people and public health were raised at County Hall, the report said, with Cllr Chris Jarman saying it may one day be viewed as “akin to asbestos.” Jarman cited NHS-related research and a case highlighted by Hull University Teaching Hospitals NHS Trust: a 15-year-old admitted with chest pain and breathing difficulty who reported cannabis use and vaping about 500 puffs per day and was diagnosed via CT with “air leak syndrome.”
Feb.27 by 2FIRSTS.ai
Puerto Rico House Files P.C. 1070 to Ban Flavored Vaping Product Sales to Under-21s
Puerto Rico House Files P.C. 1070 to Ban Flavored Vaping Product Sales to Under-21s
According to a statement from the Puerto Rico House of Representatives, House Speaker Carlos Méndez and Rep. Pedro Julio Santiago announced the filing of House Bill 1070 (P.C. 1070), which would prohibit sales to people under 21 of vaping devices, liquids, or cartridges featuring a flavor and/or aroma other than nicotine.
Jan.29 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
UK reminds vaping firms to apply for new excise duty registration from April 2026
UK reminds vaping firms to apply for new excise duty registration from April 2026
HMRC has issued a reminder urging vaping manufacturers, importers and warehouse operators to prepare for registration under the UK’s new Vaping Products Duty, with applications opening in April 2026 and the duty taking effect in October.
Feb.10
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Health Canada’s vaping compliance and enforcement report covering inspections from April 2024 to March 2025 found 43% of 546 specialty vaping businesses were not compliant with the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act, according to the report cited. Health inspectors seized vaping products at 235 specialty vaping establishments.
Feb.26 by 2FIRSTS.ai
Haypp Voluntarily Sets a 20 mg Nicotine-Strength Cap for Nicotine Pouches and Urges the UK to Establish a Regulatory Limit
Haypp Voluntarily Sets a 20 mg Nicotine-Strength Cap for Nicotine Pouches and Urges the UK to Establish a Regulatory Limit
Online nicotine pouch retailer Haypp said it has voluntarily adopted a 20 mg per pouch nicotine-strength cap across its e-commerce platforms and is urging the UK government to formalize that cap as the limit as it develops a regulatory framework. Haypp said proportionate limits would protect consumers while preserving nicotine pouches as a viable reduced-risk alternative to cigarettes.
Feb.26 by 2FIRSTS.ai